A Phase 4 interventional study of Tenofovir disoproxil fumarate in Hepatitis B, Chronic, sponsored by GlaxoSmithKline. Completed at 12 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-11-04.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing tenofovir in Hepatitis B, Chronic — none open to participants now, 1 under way, 1 of them phase 3. Tenofovir · Hepatitis B, Chronic.
Among the 50 studies testing tenofovir in Hepatitis B, Chronic, this one is the 12th largest by enrollment, is one of 7 that started in 2015, is one of 22 in phase 4, and was the 32nd registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →None of the 50 studies testing tenofovir in Hepatitis B, Chronic is open now. The open studies under Hepatitis B, Chronic, anywhere →
Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 13 · Phase 4 22
First in 2004; this study’s year is marked. 7 started in 2015.
This study's enrollment of 213 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 117 across the 50 interventional studies. Of the 37 that completed or were terminated, 17 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 50 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
30 studies in Hepatitis B, Chronic by GlaxoSmithKline: 1 open now, 2 under way, none of them phase 3. Of 28 finished, 18 (64%) have results posted.
Among the 30 studies in Hepatitis B, Chronic by GlaxoSmithKline, this one is the 11th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2015, is one of 10 in phase 4, and was the 18th registered.
GlaxoSmithKline’s Hepatitis B, Chronic studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 50 studies testing tenofovir in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 30 in Hepatitis B, Chronic:
This tab as a report to print or save as PDF → With an account.
This is a phase IV, single-arm, open-label, multi-centre study to assess the efficacy of TDF in Chronic hepatitis B (CHB) subjects following failure of multiple Nucleos(t)ide analogues (NAs). The study will enrol 200 CHB subjects following failure of multiple NAs. Subjects will be assessed for eligibility at a screening visit, with eligible subjects returning for a baseline assessment after approximately 4 weeks (Screening phase). In the treatment phase all enrolled subjects will receive open label TDF at a dose of 300 milligrams (mg) orally once daily. All the eligible study subjects will undergo safety and efficacy assessments every 12 weeks for a total of 14 visits. Tenofovir disoproxil fumarate, the oral pro-drug of tenofovir (TFV), is a nucleotide analogue that inhibits viral polymerases by direct binding and after incorporation into deoxyribonucleic acid (DNA), by termination of the DNA) chain. TDF is a highly potent treatment in treatment-naïve and lamivudine (LAM) resistant CHB patients. The purpose of our study is to evaluate the efficacy of TDF treatment in Chinese CHB patients following failure of multiple NAs. In addition, the study will also explore the relationship of baseline factors and early HBV DNA suppression to long-term virological response. The efficacy of TDF in multi-drug resistant patients will be analysed separately. The data generated by this study could then be used to optimize the clinical application of TDF and provide new evidence for management of the HBV infections following failure of multiple NAs. The result of this study will help Chinese physicians better manage the CHB patients following failure of multiple NAs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All enrolled subjects will receive open label TDF at a dose of 300 milligram (mg) orally once daily during the study period.
Drug: Tenofovir disoproxil fumarate
Tenofovir disoproxil fumarate tablets supplied will be white, almond-shaped, film-coated tablets containing 300 mg of TDF. Each tablet contains the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, pregelatinised starch, croscarmellose sodium, and magnesium stearate.
Percentage of Participants With Serum Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <20 International Unit Per Milliliter (IU/mL) at Week 144
HBV DNA level were analyzed using the sensitive HBV test in central laboratory using Roche cobas Taqman HBV test from the blood samples collected at Week 144. A 95 percent confidence interval (CI) was constructed by normal approximation and continuity correction method. Percentage of participants with serum HBV DNA \<20 IU/mL at Week 144 have been presented. The Modified Intent-to-treat (mITT) Population was defined as all recruited participants who received at least one dose of study medication.
Time frame: At Week 144
Percentage of Participants With Serum HBV DNA <20 IU/mL and Serum HBV DNA <69 IU/mL at Weeks 48 and 96
HBV DNA level were analyzed using the sensitive HBV test in central laboratory using Roche cobas Taqman HBV test from the blood samples collected at Weeks 48 and 96. Virological response was assessed by proportion of participants with serum serum HBV \<20 IU/mL and \<69 IU/mL at Weeks 48 and 96. Percentage of participants with serum HBV DNA \<20 IU/mL and \<69 IU/mL at Weeks 48 and 96 have been presented.
Time frame: At Weeks 48 and 96
Percentage of Participants in the Subgroup With Confirmed Multi-drug Resistance Mutations at Baseline With Serum HBV DNA <20 IU/mL and Serum HBV DNA <69 IU/mL at Weeks 48, 96 and 144
Serum samples were collected and analyzed for HBV DNA levels at indicated time points. Resistance surveillance of the HBV polymerase gene were performed by direct sequencing for all participants at Baseline. Day 0 was considered as Baseline. Percentage of participants in the subgroup with confirmed multi-drug resistance mutations at Baseline with serum HBV DNA \<20 IU/mL and serum HBV DNA \<69 IU/mL at Weeks 48, 96 and 144 have been presented.
Time frame: At Weeks 48, 96, and 144
Change From Baseline in Logarithm to the Base 10 (Log 10) Reduction in Serum HBV DNA at Week 48, 96 and 144
Log10 reduction in serum HBV DNA was analyzed by patterns of mutation. The patterns of mutation were summarized by 2 categories. Category 1 included wild-type, LAM-R (Lamivudine-resistant), ADV-R (Adefovir-resistant) and ETV-R (Entecavir-resistant). Category 2 included Wild type, ADV-R single mutation, ADV-R double mutation and other mutation. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
Time frame: Baseline (Day 0) and at Weeks 48,96, and 144
Percentage of Hepatitis B e Antigen (HBeAg) Positive Participants Achieving HBeAg Loss, HBeAg Seroconversion or Hepatitis B s Antigen (HBsAg) Loss and HBsAg Seroconversion at Weeks 48, 96, and 144
Serological response was assessed at Weeks 48, 96 and 144 in participants with Positive HBeAg at Baseline (Day 0). It was presented as HBeAg Loss, HBeAg Seroconversion, HBsAg Loss and HBsAg Seroconversion. HBeAg Loss was defined as HBeAg changed to be negative. HBeAg seroconversion was defined as HBeAg changed to negative and HBeAb was positive. HBsAg Loss was defined as HBsAg changed to be negative. HBsAg seroconversion was defined as HBsAg changed to negative and HBsAb was positive.
Time frame: At Weeks 48, 96 and 144
Percentage of HBeAg Negative Participants Achieving HBsAg Loss and HBsAg Seroconversion at Weeks 48, 96, and 144
Serological response was assessed at Weeks 48, 96 and 144 in participants with negative HBeAg at Baseline (Day 0). HBsAg Loss was defined as HBsAg changed to be negative. HBsAg seroconversion was defined as HBsAg changed to negative and HBsAb was positive.
Time frame: At Weeks 48,96, and 144
Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Weeks 48, 96, and 144 in Participants Who Had Abnormal ALT at Baseline
Blood samples were collected for evaluation of ALT at indicated time points. ALT normalization was defined as measurement less than or equal to the upper limit of the normal range. Normal range for ALT is 7 to 56 International Units per liter. Percentage of participants with ALT normalization at Weeks 48, 96, and 144 in Participants who had abnormal ALT at Baseline (Day 0) have been presented.
Time frame: At Weeks 48, 96, and 144
Percentage of Participants Who Experienced Viral Breakthrough up to Week 144
Viral breakthrough was defined as 1 log increase in HBV DNA from nadir determined by two sequential HBV DNA measurements. Percentage of participants who experienced viral breakthrough at Weeks 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144 have been presented.
Time frame: At Weeks 24, 36, 48, 60, 72, 84, 96, 108, 120,132, and 144
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and Non-serious TEAEs
An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is defined as AE occurred on or after the first dose date of study drug, SAE is any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, is a congenital anomaly/birth defect and other situations according to medical or scientific judgement or events associated with liver injury and impaired liver function. The Safety analysis (SA) Population was defined as all participants who received at least one dose of study medication and have at least one post Baseline safety assessment.
Time frame: Up to Week 144
Change From Baseline in Hematology Parameters: White Blood Cells (WBC), Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets
Blood samples were collected to analyze the hematology parameters: WBC, basophils, eosinophils, lymphocytes, monocytes, neutrophils and platelets. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
Time frame: Baseline (Day 0) and at Weeks 24, 48, 72, 96, 120 and 144
Change From Baseline in Hemoglobin (Hb)
Blood samples were collected to analyze Hb values. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
Time frame: Baseline (Day 0) and at Weeks 24, 48, 72, 96, 120 and 144
Change From Baseline in Red Blood Cells (RBC)
Blood samples were collected to analyze RBC values. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
Time frame: Baseline (Day 0) and at Weeks 24, 48, 72, 96, 120 and 144
Change From Baseline in Chemistry Parameters: ALT, Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-Glutamyltransferase (GGT), Creatinine Phosphokinase (CK), Lactose Dehydrogenase (LDH)
Blood samples were collected to analyze the chemistry parameters: ALT, ALP, AST, GGT, CK, LDH. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
Time frame: Baseline (Day 0) and at Weeks 12,24,36,48,60,72,84,96,108,120,132,and 144
Change From Baseline in Chemistry Parameters: Total Billirubin, Direct Bilirubin, Serum Creatinine
Blood samples were collected to analyze the chemistry parameters: total billirubin,direct bilirubin and serum creatinine. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
Time frame: Baseline (Day 0) and at Weeks, 12,24,36,48,60,72,84,96,108,120,132,and 144
Change From Baseline in Chemistry Parameters: Albumin, Total Protein
Blood samples were collected to analyze the chemistry parameters: albumin and total protein. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
Time frame: Baseline (Day 0) and at Weeks, 12,24,36,48,60,72,84,96,108,120,132,and 144
Change From Baseline in Chemistry Parameter: Blood Urea Nitrogen (BUN), Potassium, Sodium, Chloridian, Phosphorus, Calcium and Fasting Blood Glucose.
Blood samples were collected to analyze the chemistry parameters: BUN, potassium, sodium, chloridian, phosphorus, calcium and fasting blood glucose. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
Time frame: Baseline (Day 0) and at Weeks, 12,24,36,48,60,72,84,96,108,120,132,and 144
Change From Baseline in Chemistry Parameter: Creatinine Clearance Rate
Blood samples were collected to analyze the chemistry parameter: creatinine clearance rate. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
Time frame: Baseline (Day 0) and at Weeks, 12,24,36,48,60,72,84,96,108,120,132,and 144
Change From Baseline in Chemistry Parameter: Estimated Glomerular Filtration Rate (eGFR)
Blood samples were collected to analyze the chemistry parameter: eGFR. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
Time frame: Baseline (Day 0) and at Weeks, 12,24,36,48,60,72,84,96,108,120,132,and 144
This study was conducted to evaluate the efficacy and safety of Tenofovir Disoproxil Fumarate treatment in Chinese chronic hepatitis B (CHB) participants following failure of multiple Nucleos(t)ide analogues(NAs) at different centers in China.
| Milestone | Tenofovir Disoproxil Fumerate 300 mg |
|---|---|
| Started | 213 |
| Completed | 204 |
| Not completed | 9 |
| Withdrew: Adverse event | 1 |
| Withdrew: Protocol violation | 4 |
| Withdrew: Pregnancy | 2 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Lost to follow-up | 1 |
HBV DNA level were analyzed using the sensitive HBV test in central laboratory using Roche cobas Taqman HBV test from the blood samples collected at Week 144. A 95 percent confidence interval (CI) was constructed by normal approximation and continuity correction method. Percentage of participants with serum HBV DNA \<20 IU/mL at Week 144 have been presented. The Modified Intent-to-treat (mITT) Population was defined as all recruited participants who received at least one dose of study medication.
| Percentage of Participants | Tenofovir Disoproxil Fumerate 300 mg |
|---|---|
| Percentage of Participants With Serum Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <20 International Unit Per Milliliter (IU/mL) at Week 144 | 77.0 |
HBV DNA level were analyzed using the sensitive HBV test in central laboratory using Roche cobas Taqman HBV test from the blood samples collected at Weeks 48 and 96. Virological response was assessed by proportion of participants with serum serum HBV \<20 IU/mL and \<69 IU/mL at Weeks 48 and 96. Percentage of participants with serum HBV DNA \<20 IU/mL and \<69 IU/mL at Weeks 48 and 96 have been presented.
| Percentage of Participants | Tenofovir Disoproxil Fumerate 300 mg |
|---|---|
| Week 48, HBV DNA <20 IU/mL | 46.9 |
| Week 48, HBV DNA <69 IU/mL | 76.5 |
| Week 96, HBV DNA <20 IU/mL | 61.0 |
| Week 96, HBV DNA <69 IU/mL | 84.0 |
Serum samples were collected and analyzed for HBV DNA levels at indicated time points. Resistance surveillance of the HBV polymerase gene were performed by direct sequencing for all participants at Baseline. Day 0 was considered as Baseline. Percentage of participants in the subgroup with confirmed multi-drug resistance mutations at Baseline with serum HBV DNA \<20 IU/mL and serum HBV DNA \<69 IU/mL at Weeks 48, 96 and 144 have been presented.
| Percentage of Participants | Tenofovir Disoproxil Fumerate 300 mg |
|---|---|
| Week 48, HBV DNA <20 IU/mL | 34.2 |
| Week 48, HBV DNA <69 IU/mL | 60.5 |
| Week 96, HBV DNA <20 IU/mL | 55.3 |
| Week 96, HBV DNA <69 IU/mL | 76.3 |
| Week 144, HBV DNA <20 IU/mL | 65.8 |
| Week 144, HBV DNA <69 IU/mL | 84.2 |
Log10 reduction in serum HBV DNA was analyzed by patterns of mutation. The patterns of mutation were summarized by 2 categories. Category 1 included wild-type, LAM-R (Lamivudine-resistant), ADV-R (Adefovir-resistant) and ETV-R (Entecavir-resistant). Category 2 included Wild type, ADV-R single mutation, ADV-R double mutation and other mutation. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
| Log 10 (IU/mL) | Tenofovir Disoproxil Fumerate 300 mg |
|---|---|
| Category 1, Week 48, Wild type, n=57 | -2.2 ± 1.63 |
| Category 1,Week 96, Wild type, n=57 | -2.3 ± 1.61 |
| Category 1,Week 144, Wild type, n=56 | -2.4 ± 1.54 |
| Category 1,Week 48, ADV-R, n=38 | -3.0 ± 1.58 |
| Category 1, Week 96, ADV-R, n=38 | -3.3 ± 1.53 |
| Category 1, Week 144, ADV-R, n=38 | -3.5 ± 1.55 |
| Category 1, Week 48, ETV-R, n=32 | -3.2 ± 1.49 |
| Category 1, Week 96, ETV-R, n=32 | -3.4 ± 1.49 |
| Category 1, Week 144, ETV-R, n=31 | -3.6 ± 1.47 |
| Category 1, Week 48, LAM-R, n=93 | -3.1 ± 1.50 |
| Category 1, Week 96, LAM-R, n=92 | -3.3 ± 1.59 |
| Category 1, Week 144,LAM-R, n=91 | -3.2 ± 1.75 |
| Category 2, Week 48, Wild type, n=57 | -2.2 ± 1.63 |
| Category 2,Week 96, Wild type, n=57 | -2.3 ± 1.61 |
| Category 2 Week 144, Wild type, n=56 | -2.4 ± 1.54 |
| Category 2, Week 48, ADV-R single mutation, n=28 | -2.9 ± 1.69 |
| Category 2, Week 96, ADV-R, single mutation, n=28 | -3.3 ± 1.65 |
| Category 2, Week 144, ADV-R single mutation, n=28 | -3.5 ± 1.64 |
| Category 2, Week 48,ADV-R double mutation, n=10 | -3.2 ± 1.26 |
| Category 2, Week 96, ADV-R double mutation, n=10 | -3.3 ± 1.22 |
| Category 1, Week 144, ADV-R double mutation, n=10 | -3.5 ± 1.36 |
| Category 2, Week 48, other mutation, n=113 | -3.1 ± 1.48 |
| Category 2, Week 96, other mutation, n=112 | -3.2 ± 1.53 |
| Category 2, Week 144, other mutation, n=110 | -3.2 ± 1.67 |
Serological response was assessed at Weeks 48, 96 and 144 in participants with Positive HBeAg at Baseline (Day 0). It was presented as HBeAg Loss, HBeAg Seroconversion, HBsAg Loss and HBsAg Seroconversion. HBeAg Loss was defined as HBeAg changed to be negative. HBeAg seroconversion was defined as HBeAg changed to negative and HBeAb was positive. HBsAg Loss was defined as HBsAg changed to be negative. HBsAg seroconversion was defined as HBsAg changed to negative and HBsAb was positive.
| Percentage of Participants | Tenofovir Disoproxil Fumerate 300 mg |
|---|---|
| Week 48, HBeAg loss | 5.3 |
| Week 48, HBeAg seroconversion | 2.6 |
| Week 48, HBsAg loss | 0.5 |
| Week 48, HBsAg seroconversion | 0 |
| Week 96, HBeAg loss | 10.0 |
| Week 96, HBeAg seroconversion | 2.6 |
| Week 96, HBsAg loss | 0.5 |
| Week 96, HBsAg seroconversion | 0.5 |
| Week 144, HBeAg loss | 15.3 |
| Week 144, HBeAg seroconversion | 4.7 |
| Week 144, HBsAg loss | 1.1 |
| Week 144, HBsAg seroconversion | 0.5 |
Serological response was assessed at Weeks 48, 96 and 144 in participants with negative HBeAg at Baseline (Day 0). HBsAg Loss was defined as HBsAg changed to be negative. HBsAg seroconversion was defined as HBsAg changed to negative and HBsAb was positive.
| Percentage of Participants | Tenofovir Disoproxil Fumerate 300 mg |
|---|---|
| Week 48, HBsAg loss | 0 |
| Week 48, HBsAg seroconversion | 0 |
| Week 96, HBsAg loss | 0 |
| Week 96, HBsAg seroconversion | 0 |
| Week 144, HBsAg loss | 0 |
| Week 144, HBsAg seroconversion | 0 |
Blood samples were collected for evaluation of ALT at indicated time points. ALT normalization was defined as measurement less than or equal to the upper limit of the normal range. Normal range for ALT is 7 to 56 International Units per liter. Percentage of participants with ALT normalization at Weeks 48, 96, and 144 in Participants who had abnormal ALT at Baseline (Day 0) have been presented.
| Percentage of Participants | Tenofovir Disoproxil Fumerate 300 mg |
|---|---|
| Week 48 | 52.5 |
| Week 96 | 60.7 |
| Week 144 | 68.3 |
Viral breakthrough was defined as 1 log increase in HBV DNA from nadir determined by two sequential HBV DNA measurements. Percentage of participants who experienced viral breakthrough at Weeks 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144 have been presented.
| Percentage of Participants | Tenofovir Disoproxil Fumerate 300 mg |
|---|---|
| Week 24 | 0.5 |
| Week 36 | 0 |
| Week 48 | 0.5 |
| Week 60 | 0 |
| Week 72 | 0 |
| Week 84 | 0 |
| Week 96 | 0 |
| Week 108 | 0.5 |
| Week 120 | 0 |
| Week 132 | 0 |
| Week 144 | 0 |
An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is defined as AE occurred on or after the first dose date of study drug, SAE is any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, is a congenital anomaly/birth defect and other situations according to medical or scientific judgement or events associated with liver injury and impaired liver function. The Safety analysis (SA) Population was defined as all participants who received at least one dose of study medication and have at least one post Baseline safety assessment.
| Participants | Tenofovir Disoproxil Fumerate 300 mg |
|---|---|
| Any TEAEs | 124 |
| Serious TEAEs | 20 |
| Non-serious TEAEs | 117 |
Blood samples were collected to analyze the hematology parameters: WBC, basophils, eosinophils, lymphocytes, monocytes, neutrophils and platelets. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
| Billion cells per liter | Tenofovir Disoproxil Fumerate 300 mg |
|---|---|
| Week 24, WBC, n=208 | 0.19 ± 1.409 |
| Week 48, WBC, n=208 | 0.15 ± 1.470 |
| Week 72, WBC, n=207 | 0.13 ± 1.553 |
| Week 96, WBC, n=207 | 0.07 ± 1.504 |
| Week 120, WBC, n=204 | 0.10 ± 1.566 |
| Week 144, WBC, n=204 | 0.12 ± 1.484 |
| Week 24, Neutrophils, n=208 | 0.15 ± 1.322 |
| Week 48, Neutrophils, n=208 | 0.09 ± 1.419 |
| Week 72, Neutrophils, n=207 | 0.10 ± 1.388 |
| Week 96, Neutrophils, n=207 | 0.05 ± 1.414 |
| Week 120, Neutrophils, n=204 | 0.14 ± 1.400 |
| Week 144, Neutrophils, n=204 | 0.12 ± 1.293 |
| Week 24, Lymphocytes, n=208 | 0.02 ± 0.390 |
| Week 48, Lymphocytes, n=208 | 0.05 ± 0.396 |
| Week 72, Lymphocytes, n=207 | 0.02 ± 0.490 |
| Week 96, Lymphocytes, n=207 | 0.02 ± 0.439 |
| Week 120, Lymphocytes, n=204 | -0.05 ± 0.459 |
| Week 144, Lymphocyte, n=204 | 0.00 ± 0.443 |
| Week 24, Monocytes, n=208 | -0.001 ± 0.1069 |
| Week 48, Monocytes, n=208 | 0.004 ± 0.1163 |
| Week 72, Monocytes, n=207 | -0.010 ± 0.1177 |
| Week 96, Monocytes, n=207 | -0.009 ± 0.1123 |
| Week 120, Monocytes, n=204 | -0.006 ± 0.1209 |
| Week 144, Monocytes, n=204 | -0.008 ± 0.1285 |
| Week 24, Eosinophils, n=208 | 0.02 ± 0.153 |
| Week 48, Eosinophils, n=208 | -0.00 ± 0.079 |
| Week 72, Eosinophils, n=207 | 0.02 ± 0.225 |
| Week 96, Eosinophils, n=207 | -0.00 ± 0.076 |
| Week 120, Eosinophils, n=204 | 0.00 ± 0.092 |
| Week 144, Eosinophils, n=204 | 0.00 ± 0.097 |
| Week 24, Basophils, n=208 | 0.00 ± 0.027 |
| Week 48, Basophils, n=208 | 0.00 ± 0.023 |
| Week 72, Basophils, n=207 | -0.00 ± 0.025 |
| Week 96, Basophils, n=207 | -0.00 ± 0.024 |
| Week 120, Basophils, n=203 | 0.00 ± 0.025 |
| Week 144, Basophils, n=203 | 0.00 ± 0.025 |
| Week 24, Platelets, n=208 | 3.5 ± 27.07 |
| Week 48, Platelets, n=208 | 2.5 ± 29.38 |
| Week 72, Platelets, n=207 | 1.9 ± 33.74 |
| Week 96, Platelets, n=207 | 3.9 ± 33.20 |
| Week 120, Platelets, n=204 | 7.2 ± 33.48 |
| Week 144, Platelets, n=204 | 9.3 ± 34.74 |
Blood samples were collected to analyze Hb values. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
| Grams per liter | Tenofovir Disoproxil Fumerate 300 mg |
|---|---|
| Week 24, n=208 | 2.4 ± 6.53 |
| Week 48, n=208 | -0.2 ± 7.04 |
| Week 72, n=207 | -0.2 ± 7.68 |
| Week 96, n=207 | -1.0 ± 8.67 |
| Week 120, n=204 | -1.0 ± 8.86 |
| Week 144, n=204 | -0.2 ± 9.24 |
Blood samples were collected to analyze RBC values. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
| Trillion cells per liter | Tenofovir Disoproxil Fumerate 300 mg |
|---|---|
| Week 24, n=208 | 0.13 ± 0.254 |
| Week 48, n=208 | 0.05 ± 0.259 |
| Week 72, n=207 | 0.07 ± 0.268 |
| Week 96, n=207 | 0.02 ± 0.294 |
| Week 120, n=204 | 0.08 ± 0.291 |
| Week 144, n=204 | 0.06 ± 0.305 |
Blood samples were collected to analyze the chemistry parameters: ALT, ALP, AST, GGT, CK, LDH. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
| International units per liter | Tenofovir Disoproxil Fumerate 300 mg |
|---|---|
| Week 12, ALT, n=209 | 1.66 ± 54.582 |
| Week 24, ALT, n=208 | -2.80 ± 51.195 |
| Week 36, ALT, n=209 | -4.57 ± 51.811 |
| Week 48, ALT, n=208 | -7.07 ± 50.986 |
| Week 60, ALT, n=208 | -9.20 ± 50.312 |
| Week 72, ALT, n=207 | -8.12 ± 51.538 |
| Week 84, ALT, n=207 | -10.53 ± 51.781 |
| Week 96, ALT, n=207 | -9.13 ± 54.323 |
| Week 108, ALT, n=205 | -11.25 ± 52.277 |
| Week 120, ALT, n=205 | -11.95 ± 51.584 |
| Week 132, ALT, n=205 | -11.56 ± 51.594 |
| Week 144, ALT, n=204 | -10.97 ± 53.326 |
| Week 12, AST, n=209 | -1.68 ± 44.258 |
| Week 24, AST, n=208 | -3.20 ± 44.506 |
| Week 36, AST, n=209 | -2.93 ± 45.755 |
| Week 48, AST, n=205 | -4.23 ± 45.393 |
| Week 60, AST, n=208 | -4.68 ± 44.969 |
| Week 72, AST, n=207 | -4.43 ± 44.901 |
| Week 84, AST, n=207 | -5.56 ± 45.435 |
| Week 96, AST, n=207 | -4.37 ± 46.008 |
| Week 108, AST, n=205 | -5.81 ± 45.818 |
| Week 120, AST, n=205 | -5.67 ± 45.645 |
| Week 132, AST, n=205 | -6.05 ± 45.290 |
| Week 144, AST, n=204 | -5.85 ± 46.176 |
| Week 12, ALP, n=208 | 4.46 ± 11.718 |
| Week 24, ALP, n=208 | 7.22 ± 13.819 |
| Week 36, ALP, n=209 | 6.27 ± 12.609 |
| Week 48, ALP, n=208 | 8.24 ± 12.225 |
| Week 60, ALP, n=208 | 8.75 ± 14.321 |
| Week 72, ALP, n=207 | 10.06 ± 16.259 |
| Week 84, ALP, n=207 | 7.32 ± 14.478 |
| Week 96, ALP, n=207 | 8.73 ± 13.854 |
| Week 108, ALP, n=205 | 7.62 ± 15.102 |
| Week 120, ALP, n=205 | 7.54 ± 17.844 |
| Week 132, ALP, n=205 | 7.36 ± 15.802 |
| Week 144, ALP, n=205 | 7.14 ± 15.099 |
| Week 12, GGT, n=208 | -1.83 ± 18.966 |
| Week 24, GGT, n=208 | -1.83 ± 19.853 |
| Week 36, GGT, n=209 | -2.25 ± 20.205 |
| Week 48, GGT, n=207 | -1.90 ± 20.760 |
| Week 60, GGT, n=208 | -1.25 ± 22.512 |
| Week 72, GGT, n=207 | -1.45 ± 23.700 |
| Week 84, GGT, n=207 | -2.10 ± 21.532 |
| Week 96, GGT, n=207 | -2.50 ± 21.436 |
| Week 108, GGT, n=205 | -1.62 ± 22.053 |
| Week 120, GGT, n=205 | -1.61 ± 22.872 |
| Week 132, GGT, n=205 | -1.80 ± 21.897 |
| Week 144, GGT, n=203 | -0.76 ± 25.363 |
| Week 12, CK, n=206 | 10.84 ± 525.680 |
| Week 24, CK, n=198 | -9.28 ± 108.221 |
| Week 36, CK, n=201 | 13.87 ± 315.156 |
| Week 48 CK, n=206 | -21.58 ± 202.083 |
| Week 60, CK, n=205 | -22.26 ± 207.666 |
| Week 72, CK, n=206 | -13.45 ± 209.963 |
| Week 84, CK, n=207 | -17.40 ± 204.800 |
| Week 96, CK, n=207 | 26.58 ± 415.775 |
| Week 108, CK, n=199 | -20.58 ± 211.398 |
| Week 120, CK, n=203 | 0.59 ± 261.655 |
| Week 132, CK, n=204 | -19.34 ± 214.775 |
| Week 144, CK, n=204 | -7.17 ± 270.074 |
| Week 12, LDH, n=209 | 1.66 ± 54.582 |
| Week 24, LDH, n=208 | -2.80 ± 51.195 |
| Week 36, LDH, n=209 | -4.57 ± 51.811 |
| Week 48, LDH, n=208 | -7.07 ± 50.986 |
| Week 60, LDH, n=208 | -9.20 ± 50.312 |
| Week 72, LDH, n=207 | -8.12 ± 51.538 |
| Week 84, LDH, n=207 | -10.53 ± 51.781 |
| Week 96, LDH, n=207 | -9.13 ± 54.323 |
| Week 108, LDH, n=205 | -11.25 ± 52.277 |
| Week 120, LDH, n=205 | -11.95 ± 51.584 |
| Week 132, LDH, n=205 | -11.56 ± 51.594 |
| Week 144, LDH, n=204 | -10.97 ± 53.326 |
Blood samples were collected to analyze the chemistry parameters: total billirubin,direct bilirubin and serum creatinine. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
| Micromoles per liter | Tenofovir Disoproxil Fumerate 300 mg |
|---|---|
| Week 12, total bilirubin, n=209 | -0.506 ± 4.8201 |
| Week 24, total bilirubin, n=208 | -0.755 ± 5.0494 |
| Week 36, total bilirubin, n=209 | -0.878 ± 5.0063 |
| Week 48, total bilirubin, n=207 | -0.167 ± 4.8371 |
| Week 60, total bilirubin, n=208 | -0.334 ± 4.9175 |
| Week 72, total bilirubin, n=207 | -1.209 ± 5.1706 |
| Week 84, total bilirubin, n=207 | -1.112 ± 5.0813 |
| Week 96, total bilirubin, n=207 | -0.780 ± 5.1218 |
| Week 108, total bilirubin, n=205 | -0.795 ± 5.7857 |
| Week 120, total bilirubin, n=205 | -1.021 ± 5.3998 |
| Week 132, total bilirubin, n=205 | -1.471 ± 4.8998 |
| Week 144, total bilirubin, n=204 | -0.869 ± 5.4163 |
| Week 12, direct bilirubin, n=209 | -0.181 ± 2.6421 |
| Week 24, direct bilirubin, n=208 | -0.360 ± 2.2236 |
| Week 36, direct bilirubin, n=208 | -0.541 ± 3.2564 |
| Week 48, direct bilirubin, n=207 | -0.085 ± 3.0478 |
| Week 60, direct bilirubin, n=208 | -0.111 ± 3.1364 |
| Week 72, direct bilirubin, n=207 | -0.654 ± 3.7846 |
| Week 84, direct bilirubin, n=207 | -0.797 ± 3.6592 |
| Week 96, direct bilirubin, n=207 | -0.711 ± 3.3849 |
| Week 108, direct bilirubin, n=205 | -0.632 ± 3.4657 |
| Week 120, direct bilirubin, n=205 | -0.802 ± 3.6175 |
| Week 132, direct bilirubin, n=205 | -0.805 ± 3.1588 |
| Week 144, direct bilirubin, n=204 | -0.573 ± 2.8964 |
| Week 12, serum creatinine, n=209 | 2.94 ± 7.089 |
| Week 24, serum creatinine, n=208 | 1.16 ± 6.934 |
| Week 36, serum creatinine, n=209 | 0.67 ± 7.743 |
| Week 48, serum creatinine, n=208 | 1.43 ± 7.480 |
| Week 60, serum creatinine, n=208 | 0.25 ± 8.181 |
| Week 72, serum creatinine, n=206 | -1.00 ± 7.583 |
| Week 84, serum creatinine, n=207 | -0.65 ± 9.075 |
| Week 96, serum creatinine, n=207 | 0.22 ± 9.013 |
| Week 108, serum creatinine, n=204 | -0.28 ± 8.511 |
| Week 120, serum creatinine, n=205 | -1.22 ± 8.844 |
| Week 132, serum creatinine, n=205 | -0.81 ± 8.250 |
| Week 144, serum creatinine, n=203 | -1.28 ± 8.610 |
Blood samples were collected to analyze the chemistry parameters: albumin and total protein. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
| Grams per liter | Tenofovir Disoproxil Fumerate 300 mg |
|---|---|
| Week 12, albumin, n=209 | 0.22 ± 2.766 |
| Week 24, albumin, n=208 | 0.54 ± 2.722 |
| Week 36, albumin, n=209 | 0.04 ± 2.545 |
| Week 48, albumin, n=208 | 0.24 ± 2.687 |
| Week 60, albumin, n=208 | 0.38 ± 2.757 |
| Week 72, albumin, n=207 | 0.49 ± 2.890 |
| Week 84, albumin, n=207 | -0.03 ± 3.021 |
| Week 96, albumin, n=207 | 0.13 ± 2.980 |
| Week 108, albumin, n=205 | -0.56 ± 2.932 |
| Week 120, albumin, n=205 | 0.17 ± 3.272 |
| Week 132, albumin, n=205 | 0.51 ± 2.942 |
| Week 144, albumin, n=204 | 0.48 ± 3.171 |
| Week 12, total protein, n=209 | 0.31 ± 4.220 |
| Week 24, total protein, n=207 | 0.92 ± 4.322 |
| Week 36, total protein, n=209 | -0.30 ± 4.280 |
| Week 48, total protein, n=208 | -0.53 ± 4.240 |
| Week 60, total protein, n=208 | -0.32 ± 4.387 |
| Week 72, total protein, n=207 | -0.26 ± 4.540 |
| Week 84, total protein, n=207 | -0.57 ± 5.158 |
| Week 96, total protein, n=207 | -0.44 ± 5.240 |
| Week 108, total protein, n=205 | -0.21 ± 4.855 |
| Week 120, total protein, n=205 | 0.95 ± 5.361 |
| Week 132, total protein, n=205 | 1.00 ± 4.494 |
| Week 144, total protein, n=204 | 0.94 ± 4.794 |
Blood samples were collected to analyze the chemistry parameters: BUN, potassium, sodium, chloridian, phosphorus, calcium and fasting blood glucose. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
| Millimoles per liter | Tenofovir Disoproxil Fumerate 300 mg |
|---|---|
| Week 12, BUN, n=209 | -0.020 ± 1.0496 |
| Week 24, BUN, n=208 | 0.069 ± 1.0725 |
| Week 36, BUN, n=209 | 0.081 ± 1.0921 |
| Week 48, BUN, n=208 | 0.075 ± 1.0907 |
| Week 60, BUN, n=208 | 0.078 ± 1.0372 |
| Week 72, BUN, n=206 | 0.119 ± 1.1114 |
| Week 84, BUN, n=207 | 0.164 ± 1.0819 |
| Week 96, BUN, n=207 | 0.100 ± 1.0482 |
| Week 108, BUN, n=204 | 0.051 ± 1.1279 |
| Week 120, BUN, n=205 | 0.110 ± 1.1672 |
| Week 132, BUN, n=205 | 0.090 ± 1.1443 |
| Week 144, BUN, n=203 | 0.193 ± 1.2236 |
| Week 12, Potassium, n=209 | -0.029 ± 0.3391 |
| Week 24, Potassium, n=208 | 0.028 ± 0.3659 |
| Week 36, Potassium, n=209 | 0.073 ± 0.3681 |
| Week 48, Potassium, n=208 | 0.016 ± 0.3206 |
| Week 60, Potassium, n=208 | 0.014 ± 0.3622 |
| Week 72, Potassium, n=206 | -0.032 ± 0.3402 |
| Week 84, Potassium, n=206 | 0.022 ± 0.3617 |
| Week 96, Potassium, n=206 | -0.019 ± 0.3357 |
| Week 108, Potassium, n=204 | -0.023 ± 0.3326 |
| Week 120, Potassium, n=204 | -0.002 ± 0.3221 |
| Week 132, Potassium, n=204 | 0.001 ± 0.3531 |
| Week 144, Potassium, n=204 | -0.000 ± 0.3851 |
| Week 12, Sodium, n=209 | 0.31 ± 2.227 |
| Week 24, Sodium, n=208 | 0.52 ± 2.514 |
| Week 36, Sodium, n=209 | 0.23 ± 2.437 |
| Week 48, Sodium, n=208 | 0.40 ± 2.781 |
| Week 60, Sodium, n=208 | 0.59 ± 2.569 |
| Week 72, Sodium, n=206 | 0.47 ± 2.631 |
| Week 84, Sodium, n=207 | 0.54 ± 2.689 |
| Week 96, Sodium, n=206 | 0.44 ± 2.388 |
| Week 108, Sodium, n=204 | 0.05 ± 2.352 |
| Week 120, Sodium, n=204 | 0.03 ± 3.332 |
| Week 132, Sodium, n=204 | 0.35 ± 2.672 |
| Week 144, Sodium, n=204 | 0.13 ± 2.642 |
| Week 12, Chloridion n=209 | -0.23 ± 3.271 |
| Week 24, Chloridion, n=208 | -0.32 ± 3.834 |
| Week 36, Chloridion, n=209 | -0.50 ± 3.453 |
| Week 48, Chloridion, n=208 | -0.31 ± 3.601 |
| Week 60, Chloridion, n=208 | -0.37 ± 3.305 |
| Week 72, Chloridion, n=206 | -0.30 ± 3.388 |
| Week 84, Chloridion, n=207 | -0.38 ± 3.519 |
| Week 96, Chloridion, n=206 | 0.04 ± 3.418 |
| Week 108, Chloridion, n=204 | -0.27 ± 3.587 |
| Week 120, Chloridion, n=204 | -0.17 ± 4.309 |
| Week 132, Chloridion, n=204 | -0.14 ± 3.717 |
| Week 144, Chloridion, n=204 | -0.28 ± 3.855 |
| Week 12, Phosphorus, n=209 | -0.018 ± 0.1607 |
| Week 24, Phosphorus, n=208 | -0.001 ± 0.1662 |
| Week 36, Phosphorus, n=209 | -0.001 ± 0.1779 |
| Week 48, Phosphorus, n=208 | -0.008 ± 0.1634 |
| Week 60, Phosphorus, n=208 | 0.004 ± 0.1685 |
| Week 72, Phosphorus, n=207 | -0.011 ± 0.1713 |
| Week 84, Phosphorus, n=207 | -0.023 ± 0.1736 |
| Week 96, Phosphorus, n=206 | -0.019 ± 0.1669 |
| Week 108, Phosphorus, n=201 | -0.008 ± 0.1779 |
| Week 120, Phosphorus, n=203 | -0.015 ± 0.1687 |
| Week 132, Phosphorus, n=204 | 0.002 ± 0.1757 |
| Week 144, Phosphorus, n=204 | -0.016 ± 0.1692 |
| Week 12, Calcium, n=209 | -0.005 ± 0.1172 |
| Week 24, Calcium, n=208 | -0.027 ± 0.1289 |
| Week 36, Calcium, n=209 | -0.030 ± 0.1432 |
| Week 48, Calcium, n=208 | -0.041 ± 0.1375 |
| Week 60, Calcium, n=208 | -0.038 ± 0.1365 |
| Week 72, Calcium, n=207 | -0.061 ± 0.1296 |
| Week 84, Calcium, n=207 | -0.060 ± 0.1321 |
| Week 96, Calcium, n=206 | -0.051 ± 0.1198 |
| Week 108, Calcium, n=204 | -0.062 ± 0.1290 |
| Week 120, Calcium, n=204 | -0.051 ± 0.1370 |
| Week 132, Calcium, n=204 | -0.052 ± 0.1235 |
| Week 144, Calcium, n=204 | -0.050 ± 0.1393 |
| Week 12, Fasting blood glucose, n=205 | -0.088 ± 1.0006 |
| Week 24, fasting blood glucose, n=208 | -0.087 ± 0.8926 |
| Week 36, fasting blood glucose, n=208 | -0.150 ± 0.9535 |
| Week 48, fasting blood glucose, n=208 | -0.234 ± 0.8378 |
| Week 60, fasting blood glucose, n=208 | -0.206 ± 0.8658 |
| Week 72, fasting blood glucose, n=202 | -0.187 ± 0.8626 |
| Week 84, fasting blood glucose, n=207 | -0.143 ± 1.0564 |
| Week 96, fasting blood glucose, n=206 | -0.132 ± 1.1423 |
| Week 108, fasting blood glucose, n=200 | -0.230 ± 0.9042 |
| Week 120, fasting blood glucose, n=204 | -0.180 ± 0.9873 |
| Week 132, fasting blood glucose, n=204 | -0.151 ± 0.9312 |
| Week 144, fasting blood glucose, n=204 | -0.070 ± 1.0163 |
Blood samples were collected to analyze the chemistry parameter: creatinine clearance rate. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
| Milliliter per minute | Tenofovir Disoproxil Fumerate 300 mg |
|---|---|
| Week 12, n=208 | -4.564 ± 11.1192 |
| Week 24, n=208 | -2.213 ± 11.2288 |
| Week 36, n=209 | -2.311 ± 12.4693 |
| Week 48, n=208 | -3.667 ± 12.3427 |
| Week 60, n=208 | -2.053 ± 13.9768 |
| Week 72, n=206 | -0.519 ± 13.1580 |
| Week 84, n=207 | -1.065 ± 15.0315 |
| Week 96, n=207 | -2.378 ± 13.8827 |
| Week 108, n=204 | -2.512 ± 13.4608 |
| Week 120, n=203 | -0.742 ± 14.3800 |
| Week 132, n=205 | -1.499 ± 13.3816 |
| Week 144, n=203 | -0.821 ± 13.8173 |
Blood samples were collected to analyze the chemistry parameter: eGFR. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.
| Grams per liter | Tenofovir Disoproxil Fumerate 300 mg |
|---|---|
| Week 12, n=209 | -2.93 ± 7.250 |
| Week 24, n=209 | -1.11 ± 6.798 |
| Week 36, n=209 | -0.63 ± 7.558 |
| Week 48, n=208 | -1.31 ± 7.378 |
| Week 60, n=208 | -0.12 ± 8.004 |
| Week 72, n=208 | 0.84 ± 7.619 |
| Week 84, n=207 | 0.42 ± 8.731 |
| Week 96, n=207 | -0.17 ± 8.752 |
| Week 108, n=205 | 0.42 ± 8.379 |
| Week 120, n=205 | 0.77 ± 8.826 |
| Week 132, n=205 | 0.60 ± 8.098 |
| Week 144, n=204 | 0.95 ± 8.313 |
Collected over On-treatment non-serious adverse events and serious adverse events were collected up to 144 weeks from the start of the treatment. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tenofovir Disoproxil Fumerate 300 mg | 1/213 (0.5%) | 20/213 (9.4%) | 117/213 (54.9%) |
| Event | Tenofovir Disoproxil Fumerate 300 mg |
|---|---|
| Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 4/213 |
| CholelithiasisHepatobiliary disorders | 2/213 |
| Fibula fractureInjury, poisoning and procedural complications | 2/213 |
| Tibia fractureInjury, poisoning and procedural complications | 2/213 |
| Cholecystitis acuteHepatobiliary disorders | 2/213 |
| Testicular seminoma (pure)Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/213 |
| Bile duct stoneHepatobiliary disorders | 1/213 |
| Cholecystitis chronicHepatobiliary disorders | 1/213 |
| Cervical vertebral fractureInjury, poisoning and procedural complications | 1/213 |
| Limb injuryInjury, poisoning and procedural complications | 1/213 |
| Event | Tenofovir Disoproxil Fumerate 300 mg |
|---|---|
| Upper respiratory tract infectionInfections and infestations | 28/213 |
| Blood creatine phosphokinase increasedInvestigations | 12/213 |
| HypophosphataemiaMetabolism and nutrition disorders | 8/213 |
| Hepatic steatosisHepatobiliary disorders | 7/213 |
| Urinary tract infectionInfections and infestations | 4/213 |
| DiarrhoeaGastrointestinal disorders | 4/213 |
| NephrolithiasisRenal and urinary disorders | 4/213 |
| InsomniaPsychiatric disorders | 4/213 |
| HypertensionVascular disorders | 4/213 |
| Blood uric acid increasedInvestigations | 3/213 |
| Age, Continuous(Years) | Tenofovir Disoproxil Fumerate 300 mg |
|---|---|
| Mean | 42.3 ± 10.29 |
| Sex: Female, Male(Participants) | Tenofovir Disoproxil Fumerate 300 mg |
|---|---|
| Female | 27 |
| Male | 186 |
| Race/Ethnicity, Customized(Participants) | Tenofovir Disoproxil Fumerate 300 mg |
|---|---|
| Asian | 213 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2015 to primary completion in Aug 2018, 40 months.
Results were first posted in Nov 2019, 1 year 2 months after primary completion.
Of 63 phase 4 interventional studies under Hepatitis B, Chronic, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 64. This study's 40 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenofovir